RayKnowChina Research Map
Shortlist0

Fujian Medical University

福建医科大学

FuzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
5.0%Leads about 1 in 20 of China's research papers on NPC ▲ from 3.5%

Led 118 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
5
Research papers it led
118
Trials it led
17
Share of China's trials
2.9%
Share of the world's papers
3.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI

Hospitals counted here

  1. Fujian Cancer Hospital87
  2. First Affiliated Hospital of Fujian Medical University17
  3. Fujian Medical University Union Hospital3
  4. Union Hospital, Fujian Medical University Counted in the group total1
  5. Mengchao Hepatobiliary Hospital of Fujian Medical University Counted in the group total1
  6. Quanzhou First Hospital, Fujian Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.2023Radiation oncology (London, England)RCTFree full text
  2. Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  3. Appraisal of Radiologic Size Criteria for Malignant Lymph Nodes in Parotid Region in Nasopharyngeal Carcinoma: Implication for Parotid-Sparing IMRT.2026Head & neck
  4. Population-based nasopharyngeal carcinoma survival in southern China.2026British journal of cancerFree full text
  5. VMAT with CCC Algorithm Optimizes Trismus Prevention: Dose-Response Analysis of Jaw Muscles Dmean and Dmax in T3-T4 Nasopharyngeal Carcinoma.2025Technology in cancer research & treatmentFree full text
Trials on ClinicalTrials.gov6
  1. Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal CarcinomaNot yet recruitingNCT07268690Lead sponsorPhase 3Start 2026-01
  2. MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPCRecruitingNCT07331428Lead sponsorPhase 2Start 2026-06
  3. IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesRecruitingNCT07376603Lead sponsorStart 2026-01
  4. CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal CarcinomaRecruitingNCT06095154Lead sponsorPhase 3Start 2025-01
  5. Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPCNot yet recruitingNCT06095167Lead sponsorPhase 3Start 2024-01
  6. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Study sitePhase 2Start 2026-07

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
3.6%Leads about 1 in 28 of China's research papers on ESCC ▲ from 2.2%

Led 105 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
5
Research papers it led
105
Trials it led
11
Share of China's trials
1.9%
Share of the world's papers
2.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025
ThemesNeoadjuvant & combined treatmentSurgeryMolecular markers & genomics

Hospitals counted here

  1. Fujian Medical University Union Hospital49
  2. Fujian Cancer Hospital32
  3. Second Affiliated Hospital of Fujian Medical University7
  4. First Affiliated Hospital of Fujian Medical University3
  5. Affiliated Hospital of Fujian Medical University1
  6. Fuzhou First General Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.2026Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  2. Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).2025Nature communicationsRCTFree full text
  3. Comparison of indocyanine green-near-infrared fluorescence guided and traditional mediastinal lymphadenectomy during radical esophagectomy: A randomized controlled trial.2024SurgeryRCT
  4. Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.2022Surgical endoscopyRCT
  5. SRRN: A regional lymph node ratio-based staging system enhancing prognostic accuracy in esophageal squamous cell carcinoma.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov6
  1. A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal CancerNot yet recruitingNCT07788001Lead sponsorPhase 3Start 2026-10
  2. Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Lead sponsorPhase 2Start 2024-07
  3. A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Lead sponsorPhase 2Start 2024-03
  4. Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Lead sponsorPhase 2Start 2024-04
  5. Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant ChemoradiotherapyRecruitingNCT03734952Lead sponsorN/AStart 2023-05
  6. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.9%Leads about 1 in 51 of China's research papers on HCC ▲ from 1.1%

Led 288 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
5
Research papers it led
288
Trials it led
8
Share of China's trials
0.5%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Papers it led5
  1. Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity.2025Journal for immunotherapy of cancerFree full text
  2. 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.2023Journal for immunotherapy of cancerFree full text
  3. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.2022Journal for immunotherapy of cancerFree full text
  4. A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRIFree full text
  5. Performance of contrast-enhanced ultrasound liver imaging reporting and data system for differentiation of patients at risk of hepatocellular carcinoma and liver metastasis.2025Annals of medicineFree full text
Trials on ClinicalTrials.gov6
  1. Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTTRecruitingNCT06349317Lead sponsorPhase 2Start 2024-04
  2. A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT06363825Lead sponsorPhase 2Start 2024-04
  3. A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingNCT06280105Lead sponsorPhase 2Start 2024-03
  4. A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular CarcinomaRecruitingNCT05409482Lead sponsorStart 2022-08
  5. Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT05713994Lead sponsorStart 2020-05
  6. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
3.2%Leads about 1 in 31 of China's research papers on Stomach cancer

Led 316 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
17
Research papers it led
316
Trials it led
74
Share of China's trials
5.1%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025
ThemesSurgeryPeritoneal spread & advanced diseaseChemotherapy & combined treatment

Hospitals counted here

  1. Fujian Medical University Union Hospital166
  2. Fujian Cancer Hospital38
  3. First Affiliated Hospital of Fujian Medical University38
  4. Second Affiliated Hospital of Fujian Medical University28
  5. Affiliated Hospital of Fujian Medical University8
  6. Quanzhou First Hospital, Fujian Medical University Counted in the group total5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial.2024JAMA surgeryRCTFree full text
  2. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up.2022GastroenterologyRCT
  3. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.2022JAMA surgeryRCTFree full text
  4. Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.2025BMC medicineRCTFree full text
  5. Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.2025Cell reports. MedicineRCTFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT07314203Lead sponsorPhase 3Start 2026-12
  2. Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaEnrolling by invitationNCT07356466Lead sponsorEarly phase 1Start 2025-05
  3. Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06793917Lead sponsorPhase 3Start 2025-06
  4. Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical TrialRecruitingNCT07142122Lead sponsorN/AStart 2025-01
  5. Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)RecruitingNCT06945718Lead sponsorStart 2025-05
  6. Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingNCT06791083Lead sponsorPhase 2Start 2024-06

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.3%Leads about 1 in 75 of China's research papers on Retinoblastoma New since 2021

Led 4 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Quanzhou First Hospital, Fujian Medical University1
  2. First Affiliated Hospital of Fujian Medical University1
  3. First Hospital of Quanzhou Affiliated to Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.9%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 20 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University13
  2. Quanzhou First Hospital, Fujian Medical University2
  3. Second Affiliated Hospital of Fujian Medical University2
  4. Affiliated Hospital of Fujian Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
3.4%Leads about 1 in 29 of China's research papers on Gastrointestinal stromal tumour ▲ from 1.3%

Led 18 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
2
Research papers it led
18
Trials it led
4
Share of China's trials
5.4%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

Hospitals counted here

  1. Fujian Medical University Union Hospital13
  2. First Affiliated Hospital of Fujian Medical University2
  3. Xiamen Humanity Hospital2
  4. Zhangzhou Municipal Hospital, Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features.2023La Radiologia medicaRCT
  2. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.2022La Radiologia medicaRCT
  3. Gastrointestinal Bleeding in Small Intestinal Stromal Tumors: A Clinicopathological and Survival Analysis.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  4. Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.2025BMC gastroenterologyFree full text
  5. A novel prognostic system for locally advanced gastrointestinal stromal tumors after neoadjuvant imatinib therapy based on the metro-ticket paradigm: a retrospective dual-center study.2025Surgical endoscopy
Trials on ClinicalTrials.gov6
  1. A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal TumorsRecruitingNCT05938309Lead sponsorStart 2023-05
  2. Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable SiteRecruitingNCT03716089Lead sponsorStart 2018-10
  3. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  4. Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GISTActive, not recruitingNCT07837271Lead sponsorStart 2026-01
  5. Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GISTNot yet recruitingNCT05970900Lead sponsorPhase 3Start 2023-10
  6. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.3%Leads about 1 in 75 of China's research papers on Neuroblastoma ▲ from 0.8%

Led 15 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University5
  2. Affiliated Hospital of Fujian Medical University2
  3. Fujian Children's Hospital2
  4. Fujian Cancer Hospital1
  5. Quanzhou First Hospital, Fujian Medical University1
  6. Fujian Medical University Union Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Using machine learning techniques predicts prognosis of patients with Ewing sarcoma.2021Journal of orthopaedic research : official publication of the Orthopaedic Research SocietyRCT
  2. A Case of Pancreatic Ewing Sarcoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.7%Leads about 1 in 60 of China's research papers on Myeloma

Led 28 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025
ThemesDiagnosis, MRD & riskBispecific & antibody drugsDrug combinations

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University15
  2. Fujian Medical University Union Hospital6
  3. Second Affiliated Hospital of Fujian Medical University2
  4. Affiliated Fuzhou First Hospital of Fujian Medical University1
  5. Fuzhou University Affiliated Provincial Hospital Counted in the group total1
  6. Ningde Mindong Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.2026Journal of chemotherapy (Florence, Italy)
  2. The value of multiparametric functional MRI histogram features in assessing multiple myeloma activity.2025European radiology
  3. Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.2025Scientific reportsFree full text
  4. [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.2024European journal of nuclear medicine and molecular imaging
  5. Multiple myeloma identified within the same site of the mandible with medication-related osteonecrosis of jaw: An unusual case report.2023MedicineFree full text
Trials on ClinicalTrials.gov6
  1. Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative DiseasesRecruitingNCT04504526Lead sponsorEarly phase 1Start 2020-08
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  4. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  5. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
2.2%Leads about 1 in 45 of China's research papers on B-ALL

Led 5 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesPhiladelphia chromosome & geneticsChildren

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Fujian Medical University Union Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.2025Pharmacogenetics and genomicsFree full text
  2. UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia.2025Cell death & diseaseFree full text
  3. Stable isotope tracing reveals glucose metabolism characteristics of drug-resistant B-cell acute lymphoblastic leukemia.2025Analytica chimica acta
  4. Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.2024BMC cancerFree full text
  5. Long Non-Coding RNA RP11-252C15.1 Is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-Cell Precursor Acute Lymphoblastic Leukemia.2024Acta haematologica
Trials on ClinicalTrials.gov6
  1. Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT07491263Lead sponsorPhase 1Start 2026-05
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  3. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  5. CART-19 Cells For R/R B-ALLStatus unknownNCT03391739Lead sponsorPhase 2/Phase 3Start 2016-01
  6. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.0%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▲ from 0.4%

Led 4 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025
ThemesImmunosuppressive treatmentClonal evolution & PNH

Hospitals counted here

  1. Fujian Medical University Union Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
4.5%Leads about 1 in 22 of China's research papers on Beta thalassaemia ▲ from 1.8%

Led 14 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025

Hospitals counted here

  1. Child Health Hospital, Fujian Medical University8
  2. Second Affiliated Hospital of Fujian Medical University3
  3. Child Health Hospital1
  4. Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.9%Leads about 1 in 34 of China's research papers on Haemophilia A ▲ from 1.3%

Led 8 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Fujian Medical University Union Hospital6
  2. Second Affiliated Hospital of Fujian Medical University1
  3. Medical University Affiliated First Quanzhou Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Standard dose and low-dose rituximab combined with glucocorticoids and cyclophosphamide in the treatment of acquired haemophilia A.2025Frontiers in immunology
  2. Development and validation of an innovative approach to estimating FVIII levels and designing personalised doses in the prophylactic treatment of haemophilia A: based on the principle of the two-compartment model.2025BMJ open
  3. Perioperative Management of Hemophilia A Patients Undergoing Cardiac Surgery: A Literature Review of Published Cases.2021Journal of cardiothoracic and vascular anesthesia
  4. Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia.2025Annals of hematology
  5. Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.2024International immunopharmacology
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  4. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  5. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  6. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
4.4%Leads about 1 in 23 of China's research papers on Fanconi anaemia New since 2021

Led 3 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Fujian Medical University Union Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.2%Leads about 1 in 81 of China's research papers on NMOSD ▲ from 0.7%

Led 6 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025
ThemesAntibodies & diagnosisBiologic drugsAcute attack treatment

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University4
  2. Second Affiliated Hospital of Fujian Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.6%Leads under 1 in 100 of China's research papers on Myasthenia gravis New since 2021

Led 3 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025
ThemesStandard immunotherapyThymus & thymectomy

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University2
  2. Second Affiliated Hospital of Fujian Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.1%Leads about 1 in 89 of China's research papers on Moyamoya

Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025
ThemesImaging & blood flowRevascularisation surgeryChildren

Hospitals counted here

  1. Fujian Medical University Union Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
2.0%Leads about 1 in 50 of China's research papers on Wilson disease ▲ from 1.0%

Led 4 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
1
Research papers it led
4
Trials it led
1
Share of China's trials
6.2%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025
ThemesGenetics (ATP7B)Diagnosis & copper testsBrain & movement symptoms

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
2.3%Leads about 1 in 43 of China's research papers on Biliary atresia ▲ from 0.8%

Led 5 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 222025
ThemesScreening & diagnosisDisease mechanisms

Hospitals counted here

  1. Second Affiliated Hospital of Fujian Medical University2
  2. Child Health Hospital, Fujian Medical University Counted in the group total1
  3. Child Health Hospital1
  4. Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.8%Leads under 1 in 100 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 2 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.9%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 9 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Hospitals counted here

  1. Fujian Medical University Union Hospital4
  2. Second Affiliated Hospital of Fujian Medical University2
  3. First Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
2.3%Leads about 1 in 43 of China's research papers on Amyotrophic lateral sclerosis ▼ from 3.4%

Led 18 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
1
Research papers it led
18
Trials it led
1
Share of China's trials
1.8%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Fujian Medical University Union Hospital11
  2. First Affiliated Hospital of Fujian Medical University6
  3. Union Hospital, Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
0.0%Leads none of China's research papers on Spinal muscular atrophy

Led 0 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
1
Research papers it led
0
Trials it led
2
Share of China's trials
6.7%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov4
  1. A Registered Cohort Study on SMARecruitingNCT04010604Lead sponsorStart 2019-07
  2. Antisense Oligonucleotide for Spinal Muscular AtrophyStatus unknownNCT05187260Lead sponsorStart 2022-01
  3. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01
  4. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
2.8%Leads about 1 in 35 of China's research papers on Duchenne muscular dystrophy ▲ from 2.0%

Led 6 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
1
Research papers it led
6
Trials it led
1
Share of China's trials
5.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University5
  2. Fujian Medical University Union Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease ▲ from 0.7%

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University2
  2. Second Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.9%Leads under 1 in 100 of China's research papers on IgA nephropathy ▲ from 0.3%

Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University3
  2. Quanzhou First Hospital, Fujian Medical University1
  3. Second Affiliated Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.3%Leads about 1 in 75 of China's research papers on Primary biliary cholangitis ▲ from 0.7%

Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University2
  2. Second Affiliated Hospital of Fujian Medical University1
  3. Affiliated Sanming First Hospital of Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
3.0%Leads about 1 in 33 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 3 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Fujian Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
5.6%Leads about 1 in 18 of China's research papers on Hirschsprung disease New since 2021

Led 9 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Affiliated Hospital of Fujian Medical University3
  2. First Affiliated Hospital of Fujian Medical University2
  3. Union Hospital, Fujian Medical University1
  4. Fujian Medical University Union Hospital1
  5. Quanzhou First Hospital, Fujian Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov